Nanomedical Diagnostics launches a new graphene biosensor with unprecedented functionality for small molecule and protein analysis
San Diego, CA (PRWEB) February 16, 2016 -- Nanomedical Diagnostics, a biotech company developing and commercializing bioelectronics for use in research and diagnostics, announces the completion of its first AGILE biosensor Early Access Development Kit test with a lab at the University of Colorado Anschutz Medical Campus. The lab needed in vitro protein concentration measurements to validate its RNA data, but doing so using traditional protein analysis methods such as Western Blot was almost impossible due to the amount of tissue required to observe the protein. The AGILE platform provided quantitative, reproducible protein concentration data in one afternoon. “This technology is a game-changer for developmental biologists,” says Dr. David Clouthier, Professor in the Department of Craniofacial Biology at the University of Colorado Anschutz Medical Campus. “It opens the field of proteomics to a discipline that’s previously used just RNA data because it was cost-prohibitive to gain the quantity of protein needed for detection on traditional platforms.”
AGILE requires an immensely smaller amount of starting material than traditional methods, which reduced sample costs for Dr. Clouthier’s lab. Because AGILE can sense protein in crude tissue lysates with high sensitivity, the lab was also able to avoid protein loss from multiple purification steps. “We’re very pleased with Nanomedical Diagnostics’ AGILE technology,” continued Dr. Clouthier. “We expect to use the gathered data in a publication this year and are looking forward to future work with AGILE sensors.”
AGILE (Automatic Graphene Immunolinked Electronic) is the world’s first and only commercially available graphene biosensor. It is an all-electronic, portable, label-free system that provides real-time analysis of biomolecular interactions including kinetics, affinity, and concentration.
“We’re excited to begin our Early Access Dev Kit tests with researchers who are on the cutting edge of their fields,” says Nanomedical Diagnostics CEO, Ross Bundy. “AGILE sensors have unprecedented flexibility and sensing range which enable unique capabilities that we’re only just beginning to discover and publish with our Early Access customers. We’re already finding instances where the novel technology is enabling scientists to accelerate their research and accomplish science that’s never been possible before.”
AGILE sensors are now available to participants in Nanomedical Diagnostics’ Early Access Dev Kit program. The company will be showcasing AGILE technology at MnM’s Biomarker Conference on February 18 and 19, and at the Experimental Biology Conference from April 2nd through 6th, both in San Diego.
For more information about Nanomedical Diagnostics or AGILE Sensors, including Early Access Dev Kit opportunities, visit http://www.nanomedicaldiagnostics.com.
About Nanomedical Diagnostics
Nanomedical Diagnostics is a biotech company based in San Diego, CA. Begun in late 2013, it is the first company to combine expertise in biology, nanotechnology, surface chemistry, engineering, and manufacturing to create practical and scaleable graphene biological field effect transistor (BioFET) products. Its ongoing mission is applying cutting-edge capabilities to produce affordable diagnostic and monitoring platforms that deliver accurate, timely health information and improve patient outcomes and lives.
Angela Shue, Nanomedical Diagnostics, Inc., http://www.nanomedicaldiagnostics.com, +1 (858) 255-4330, [email protected]
Share this article